679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This real-world study is crucial for understanding the practical effectiveness of oral semaglutide in a specific demographic, providing valuable data beyond controlled clinical trials. The findings, once published, co…
Understanding the genetic underpinnings of oral semaglutide response is crucial for advancing personalized medicine in prediabetes and obesity. This research could pave the way for personalized treatment strategies, o…
This trial holds significant promise as it explores a novel therapeutic strategy for a complex and underserved patient population. If semaglutide proves effective in reducing alcohol intake and smoking, it could offer…
The successful demonstration of bioequivalence between these two Semaglutide concentrations is critically important for manufacturing flexibility and potentially expanding treatment options. This allows Novo Nordisk t…
This study is profoundly significant because GLP-1RAs could offer a dual benefit for Type 2 Diabetes patients, simultaneously managing blood glucose and addressing nicotine dependence, a major and often overlooked com…
The finding that tirzepatide pharmacokinetics are not significantly altered by renal impairment is highly significant. This suggests that patients with kidney disease, including those with end-stage renal disease (ESR…
This research holds significant promise for a population in dire need of improved treatment options, as patients with schizophrenia and AUD face unique challenges and poorer prognoses. If successful, this study could …
This study is critical because it directly addresses a common clinical scenario: how to optimize treatment for Type 2 Diabetes patients who may not be achieving their goals on existing GLP-1 RA therapy. The expected s…
Obesity-related male infertility is a growing concern, and current treatments often lack sustained efficacy or adherence. This trial holds the potential to identify a novel and effective pharmacological intervention f…
This study provides crucial real-world evidence suggesting that GLP-1 RAs may not be safe for all patients with Type 2 Diabetes, especially those who have undergone gastrostomy. The observed increase in mortality and …
This comprehensive review solidifies the understanding of GLP-1 RAs as promising therapeutic agents for liver diseases, extending their utility beyond metabolic control. By detailing their impact on both metabolic and…
This case report provides compelling evidence that oral semaglutide could be a highly effective and well-tolerated treatment option for patients with HNF4A-MODY, potentially offering a valuable alternative to traditio…
This research highlights a potentially novel benefit of GLP-1 receptor agonists beyond their established metabolic effects, suggesting they may play a protective role in surgical recovery. The significant reduction in…
This real-world comparative study provides crucial insights into the relative effectiveness of leading weight loss medications outside of controlled clinical trials. The findings strongly support Tirzepatide's superio…
This research is critically important because it addresses a significant unmet need for overweight type 2 diabetic patients with IBD, a population facing compounded health challenges. Current IBD therapies are often l…
Understanding ethnic differences in drug response is critical for optimizing dosing and ensuring drug safety globally. Data from studies like this help inform appropriate prescribing practices for diverse populations,…
If successful, this study could highlight a novel therapeutic benefit of semaglutide beyond its established roles in glycemic control and weight management. Identifying an effective pharmacological intervention for di…
While specific numerical outcomes from this completed trial (NCT03882970) are not detailed in the provided record, the study's primary objective was to demonstrate the superior efficacy of tirzepatide in improving gly…
The findings from this review highlight a novel therapeutic pathway for Alcohol Use Disorder (AUD), leveraging Semaglutide's known effects on appetite and reward systems. Given the significant unmet need for effective…
This comprehensive review underscores the significant potential of GLP-1 RAs as novel therapeutic agents for a range of psychiatric disorders, extending their utility beyond metabolic health. Their established safety …
This retraction is a critical reminder of the importance of scientific integrity and rigorous peer review in maintaining the reliability of medical literature. It underscores that any conclusions or recommendations ba…
This review underscores the profound and expanding therapeutic potential of GLP-1 receptor agonists, solidifying their role as cornerstone treatments for type 2 diabetes and obesity. The confirmed cardiovascular and r…
This scoping review is crucial for informing clinical guidelines and best practices for orthopedic surgeons, anesthesiologists, and perioperative care teams. Understanding the current evidence base regarding GLP-1 RA …
This review provides a strong theoretical and preliminary clinical basis for exploring GLP-1 RAs as novel adjuncts to cancer immunotherapy. The observed immunomodulatory effects and potential for enhanced efficacy, co…
This FDA approval of higher-dose semaglutide marks a significant advancement in the pharmacological treatment of obesity, offering a highly effective option for chronic weight management. The substantial and sustained…
This study's design was significant because it aimed to provide a head-to-head comparison of two distinct and highly effective drug classes—a GLP-1 receptor agonist and an SGLT2 inhibitor—in a critical patient populat…
Understanding the precise gastric emptying kinetics in both healthy individuals and GLP-1 agonist users is critically important for optimizing treatment strategies and patient safety. The findings could lead to update…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
The commentary underscores the transformative potential of Semaglutide in addressing the multifaceted challenges of obesity and its associated comorbidities. Its demonstrated efficacy across multiple physiological sys…
This comprehensive meta-analysis provides compelling and robust evidence that GLP-1 and dual GIP/GLP-1 receptor agonists offer substantial and multifaceted benefits for obese patients with HFpEF, extending significant…
This research highlights the superior patient experience and satisfaction associated with switching to Tirzepatide over escalating Dulaglutide in Type 2 Diabetes management. These findings provide crucial real-world e…
This review provides crucial evidence to guide clinical decision-making and optimize the allocation of these highly effective therapies, especially in healthcare systems facing resource constraints. By identifying spe…
This study provides crucial insights into the financial sustainability of covering highly effective, yet expensive, medications like Semaglutide within Medicare. The findings underscore the the significant potential f…
This study provides compelling evidence that semaglutide offers a dual therapeutic benefit, simultaneously addressing liver fibrosis and cardiovascular risk in patients already at high risk for advanced liver disease.…
While this specific study was withdrawn, the broader context of its aims remains highly relevant for Type 2 Diabetes management. Understanding real-world effectiveness and adherence is crucial for optimizing patient o…
Understanding the interplay between GLP-1 receptor agonists like semaglutide and the ghrelin system is crucial for optimizing obesity treatments. If blocking the ghrelin receptor with LEAP2 proves beneficial, it could…
This research holds significant promise as it investigates a novel approach to treating psoriasis by targeting its metabolic underpinnings, rather than just skin symptoms. If successful, it could demonstrate that Sema…
This study is crucial for enhancing patient safety during surgical procedures for individuals on GLP-1 agonists. The findings will help identify specific patient populations who require additional risk stratification,…
The withdrawal of this study means a valuable opportunity to directly compare these important first-line diabetes treatments has been lost. Had it proceeded, the trial could have provided critical head-to-head data, p…